Tackling the Challenges Involved with Protein Biomarkers

Check out a discussion of the hottest tips and trends in the emerging field of protein biomarkers.

By | July 5, 2012

This webinar brings together experts who will discuss new approaches for dealing with everything from enriching the target protein molecule to methods now in use for isolating and detecting molecules, for biomarker discovery and applications.

Protein biomarkers have been hailed as vital stepping stones in the race to personalize medicine. But many hurdles remain to be cleared before their application becomes routine. Currently, protein biomarkers have proven useful in drug discovery and development, as tools for target discovery and evaluation of a drug’s mechanism of action, and in therapies for prevention, early detection, diagnosis, and treatment of disease. Although single markers are in use, more widespread adoption will probably require a multiplexed panel capable of detecting and measuring biomarkers accurately, inexpensively, and easily in biological samples that are highly complex.

Before a biomarker can be put to use, it must undergo several stages of confirmation, validation, and qualification depending on its intended use. Sample preparation involves many challenges. Once an appropriate method has been chosen to isolate and measure the biomarker or pattern of markers, technical parameters of the assay must be defined to establish its sensitivity, specificity, reproducibility, and reliability.

This webinar, “Tackling the Challenges Involved with Protein Biomarkers,” brings together two experts who will discuss new approaches for dealing with everything from enriching the target protein molecule to methods now in use for isolating and detecting molecules, for biomarker discovery and applications. Following the presentations, the audience will have an opportunity to ask questions concerning their specific applications and receive answers in real-time.

Meet the Speakers


Dr. Katherine Williams is an assistant professor in the Department of Obstetrics, Gynecology, and Reproductive Sciences at the University of California, San Francisco, and is a senior member of the Sandler-Moore Mass Spectrometry Core Facility. Her research program is focused on using proteomics for biomarker discovery and verification in a wide range of human disease biology.

 

Dr. Lance Liotta is a tenured professor at George Mason University in the Department of Systems Biology, College of Science. He was one of the first scientists to investigate the process of tumor invasion and metastasis at the molecular level. Liotta has invented and patented technologies in the fields of diagnostics, nanotechnology (hydrogel nanoparticles for biomarker harvesting), microdissection (laser capture microdissection ) and proteomics (reverse-phase protein microarrays) that have been used to make broad discoveries in cancer biology and cancer therapy.

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

Avatar of: Deb Davis

Deb Davis

Posts: 1

July 12, 2012

IS CD117 included in this group? Kit + (documentation found on a pathology report of a GIST biopsy.)  I'd appreciate any discussion regarding this and how its used for staging and risk for regrowth, or resistance to gleevec, or other meds...pre-resection & as adjuvent protocol!  Thanks in advance for your expertise. 

Popular Now

  1. How Plants Evolved Different Ways to Make Caffeine
  2. Thomson Reuters Predicts Nobelists
    The Nutshell Thomson Reuters Predicts Nobelists

    According to citation statistics, researchers behind programmed cell death pathways and CRISPR/Cas9 are among those in line for Nobel Prizes this year.

  3. Monsanto Buys Rights to CRISPR
    The Nutshell Monsanto Buys Rights to CRISPR

    The US agribusiness secures a global, nonexclusive licensing agreement from the Broad Institute to use the gene-editing technology for agricultural applications.

  4. Reviewing Results-Free Manuscripts
    The Nutshell Reviewing Results-Free Manuscripts

    An open-access journal is trialing a peer-review process in which reviewers do not have access to the results or discussion sections of submitted papers.

RayBiotech